|
|
|
|
| LEADER |
01559nam a2200229 u 4500 |
| 001 |
EB002000569 |
| 003 |
EBX01000000000000001163470 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 130 |
0 |
|
|a Point-of-care testing of international normalized ratio for patients on oral anticoagulant therapy (July 2014)
|
| 245 |
0 |
0 |
|a Point-of-care testing of international normalized ratio for patients on oral anticoagulant therapy
|h Elektronische Ressource
|b systematic review and economic analysis
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c 2014, July 2014
|
| 300 |
|
|
|a 1 PDF file (viix, 152 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH optimal use report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK361419
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The objectives of this health technology assessment were to evaluate the accuracy, and clinical and cost-effectiveness of point-of-care (POC) international normalized ratio (INR) devices compared with standard lab testing, and between POC INR devices. A systematic review was performed to evaluate the accuracy and clinical effectiveness of POC INR. We also performed a primary economic analysis of the cost-effectiveness of POC INR from a Canadian perspective, as well as a review of the health services impact in Canada
|